CORT Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 39.21%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 59.76%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 6.54%. Given that Corcept Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.56% to investors and pays a quarterly dividend of $0.79 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 96.73x while Gilead Sciences, Inc.'s PE ratio is 18.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.66x versus 5.30x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 21.47%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Johnson & Johnson's return on equity of 33.27%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 59.76%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could grow by 0.03%. Given that Corcept Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Corcept Therapeutics, Inc. is more attractive than Johnson & Johnson.

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.54% to investors and pays a quarterly dividend of $1.30 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Johnson & Johnson's net income of $5.2B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 96.73x while Johnson & Johnson's PE ratio is 19.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.66x versus 5.33x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 33.68%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Merck & Co., Inc.'s return on equity of 39.63%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 59.76%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.92 which suggests that it could grow by 4.99%. Given that Corcept Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.21% to investors and pays a quarterly dividend of $0.81 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 96.73x while Merck & Co., Inc.'s PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.66x versus 3.98x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 34.76%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Corcept Therapeutics, Inc. has a consensus price target of $135.25, signalling upside risk potential of 59.76%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 6.12%. Given that Corcept Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 96.73x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.66x versus 10.10x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.